CPC A61L 27/3895 (2013.01) [A61K 35/42 (2013.01); A61L 27/3804 (2013.01); A61L 27/3813 (2013.01); A61L 27/3834 (2013.01); A61L 27/3839 (2013.01); A61L 27/3869 (2013.01); C12N 5/0018 (2013.01); C12N 5/0062 (2013.01); C12N 5/0606 (2013.01); C12N 5/0607 (2013.01); C12N 5/0688 (2013.01); C12N 5/0689 (2013.01); A61L 2430/22 (2013.01); C12N 2501/113 (2013.01); C12N 2501/115 (2013.01); C12N 2501/117 (2013.01); C12N 2501/119 (2013.01); C12N 2501/155 (2013.01); C12N 2501/385 (2013.01); C12N 2501/415 (2013.01); C12N 2501/999 (2013.01); C12N 2506/02 (2013.01); C12N 2506/03 (2013.01); C12N 2506/27 (2013.01); C12N 2506/45 (2013.01); C12N 2513/00 (2013.01)] | 11 Claims |
1. A method, comprising:
culturing in vitro for approximately forty days cells from NKX2.1+ ventral-anterior foregut spheroid tissue derived from pluripotent stem cells, wherein the culturing results in differentiation of the cells from the NKX2.1+ ventral-anterior foregut spheroid tissue derived from pluripotent stem cells into tissue comprising 3-dimensional lung-like epithelium, wherein the culturing comprises activating the FGF signaling pathway, the retinoic acid signaling pathway, and the Wnt signaling pathway; and
obtaining 3-dimensional lung tissue from the cultured tissue comprising 3-dimensional lung-like epithelium, wherein the obtained 3-dimensional lung tissue comprises a 3-dimensional lung tissue peripheral region and a 3-dimenstional lung tissue internal region,
wherein the 3-dimensional lung tissue peripheral region comprises cells expressing SOX9 protein and SOX2 protein,
wherein the 3-dimensional lung tissue internal region comprises cells expressing SOX2 protein, SCGB1A1 protein, and MUC5AC, wherein the 3-dimensional lung tissue internal region does not comprise cells expressing SOX9 protein.
|